177 related articles for article (PubMed ID: 16172229)
1. Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002.
Saraiya M; Kottiri BJ; Leadbetter S; Blackman D; Thompson T; McKenna MT; Stallings FL
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2178-82. PubMed ID: 16172229
[TBL] [Abstract][Full Text] [Related]
2. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
4. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
Porter MP; Stanford JL; Lange PH
Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
[TBL] [Abstract][Full Text] [Related]
5. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
Gann PH; Ma J; Catalona WJ; Stampfer MJ
J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen reference ranges in Saudi men.
Kamal BA; Ali GA; Taha SA
Saudi Med J; 2003 Jun; 24(6):665-8. PubMed ID: 12847600
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
8. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
Merrill RM
Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
[TBL] [Abstract][Full Text] [Related]
10. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers.
Ornstein DK; Smith DS; Rao GS; Basler JW; Ratliff TL; Catalona WJ
J Urol; 1997 Jun; 157(6):2179-82. PubMed ID: 9146610
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
13. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
[TBL] [Abstract][Full Text] [Related]
14. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
[TBL] [Abstract][Full Text] [Related]
15. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
16. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
[TBL] [Abstract][Full Text] [Related]
18. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
Roddam AW; Hamdy FC; Allen NE; Price CP;
BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
[TBL] [Abstract][Full Text] [Related]
19. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
20. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]